New drug combo aims to shrink advanced cervical cancer
NCT ID NCT06238635
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial is testing whether combining two immunotherapy drugs, dostarlimab and cobolimab, can shrink tumors or slow the growth of advanced cervical cancer that has spread or returned. About 66 participants with measurable disease will receive the drugs by IV. The main goal is to see how many people respond, with secondary goals including how long the cancer stays under control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
dostarlimab and cobolimab (two immunotherapy drugs given by IV)
What this could lead to
If it works, this combination could offer a new treatment option for people with advanced cervical cancer that has spread or come back.
What could go wrong
This is a small, early-phase trial (66 people) with no control group, so results may not apply broadly. Immunotherapy can cause immune-related side effects like inflammation in healthy organs.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States